These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19521244)

  • 21. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
    Kishnani PS; Nicolino M; Voit T; Rogers RC; Tsai AC; Waterson J; Herman GE; Amalfitano A; Thurberg BL; Richards S; Davison M; Corzo D; Chen YT
    J Pediatr; 2006 Jul; 149(1):89-97. PubMed ID: 16860134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases.
    Manwaring V; Prunty H; Bainbridge K; Burke D; Finnegan N; Franses R; Lam A; Vellodi A; Heales S
    J Inherit Metab Dis; 2012 Mar; 35(2):311-6. PubMed ID: 21687968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a kit for urine collection on filter paper as an alternative for Pompe disease screening and monitoring by LC-HRMS.
    de Souza HMR; Scalco FB; Garrett R; de C Marques FF
    Anal Methods; 2023 Aug; 15(32):3932-3939. PubMed ID: 37539791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrocardiographic response to enzyme replacement therapy for Pompe disease.
    Ansong AK; Li JS; Nozik-Grayck E; Ing R; Kravitz RM; Idriss SF; Kanter RJ; Rice H; Chen YT; Kishnani PS
    Genet Med; 2006 May; 8(5):297-301. PubMed ID: 16702879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry.
    Rozaklis T; Ramsay SL; Whitfield PD; Ranieri E; Hopwood JJ; Meikle PJ
    Clin Chem; 2002 Jan; 48(1):131-9. PubMed ID: 11751548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.
    Cook AL; Kishnani PS; Carboni MP; Kanter RJ; Chen YT; Ansong AK; Kravitz RM; Rice H; Li JS
    Genet Med; 2006 May; 8(5):313-7. PubMed ID: 16702882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late form of Pompe disease with glycogen storage in peripheral nerves axons.
    Fidziańska A; Ługowska A; Tylki-Szymańska A
    J Neurol Sci; 2011 Feb; 301(1-2):59-62. PubMed ID: 21109266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of muscle pathology in infantile Pompe disease.
    Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
    Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study.
    Deroma L; Guerra M; Sechi A; Ciana G; Cisilino G; Dardis A; Bembi B
    Eur J Pediatr; 2014 Jun; 173(6):805-13. PubMed ID: 24395639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction.
    Li C; Desai AK; Gupta P; Dempsey K; Bhambhani V; Hopkin RJ; Ficicioglu C; Tanpaiboon P; Craigen WJ; Rosenberg AS; Kishnani PS
    Genet Med; 2021 May; 23(5):845-855. PubMed ID: 33495531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases.
    Sluiter W; van den Bosch JC; Goudriaan DA; van Gelder CM; de Vries JM; Huijmans JG; Reuser AJ; van der Ploeg AT; Ruijter GJ
    Clin Chem; 2012 Jul; 58(7):1139-47. PubMed ID: 22623745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
    Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
    But WM; Lee SH; Chan AO; Lau GT
    Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.